Sugi Predict

Sugi Predict / Compounds / SCHEMBL328476

SCHEMBL328476

SCHEMBL328476

O=C(O)CCC(CCC(=O)O)(CCC(=O)O)NC(=O)OCc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 1/20 0.57
▸ KMT2A Q03164 2/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.49
▸ LMNA P02545 1/20 0.49
▸ CA12 O43570 2/20 0.48
▸ CA1 P00915 2/20 0.48
▸ CA2 P00918 2/20 0.48
▸ CA9 Q16790 2/20 0.48
▸ NPC1 O15118 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ POLB P06746 1/20 0.47
▸ ALDH1A1 P00352 3/20 0.46
▸ CPB1 P15086 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ SLC6A2 P23975 1/20 0.45
▸ SLC6A3 Q01959 1/20 0.45
▸ TDP1 Q9NUW8 1/20 0.45
▸ CTRB1 P17538 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22829843 0.88 HTT (0.47) HTTKMT2AMEN1SMN1; SMN2LMNA
SCHEMBL19477840 0.86 HTT (0.57) HTTKMT2AMEN1SMN1; SMN2LMNA
SCHEMBL19477935 0.85 HTT (0.44) HTTKMT2AMEN1SMN1; SMN2LMNA
SCHEMBL16094095 0.85 HTT (0.63) HTTKMT2AMEN1SMN1; SMN2LMNA
SCHEMBL8700050 0.85 HTT (0.55) HTTKMT2AMEN1SMN1; SMN2LMNA
SCHEMBL25746327 0.85 HTT (0.55) HTTKMT2AMEN1SMN1; SMN2LMNA
SCHEMBL11524103 0.85 HTT (0.55) HTTKMT2AMEN1SMN1; SMN2LMNA
SCHEMBL328631 0.83 SYK (0.49) HTTKMT2AMEN1SMN1; SMN2LMNA
SCHEMBL15829787 0.83 KMT2A (0.50) HTTKMT2AMEN1SMN1; SMN2LMNA
SCHEMBL9087628 0.82 HTT (0.52) HTTKMT2AMEN1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179496-A1 TARGETED COMPOSITIONS ARBUTUS BIOPHARMA CORPORATION (US) 2025-06-05 — — US disclosed
US-12043833-B2 Targeted compositions ARBUTUS BIOPHARMA CORPORATION (CA) 2024-07-23 — — US disclosed
US-12043833-B2 Targeted compositions ARBUTUS BIOPHARMA CORPORATION (CA) 2024-07-23 — — US disclosed
US-20230279041-A1 FUNCTIONALIZED N-ACETYLGALACTOSAMINE ANALOGS HONGENE BIOTECH CORPORATION 2023-09-07 — — US disclosed
US-11427823-B2 Targeted compositions ARBUTUS BIOPHARMA CORPORATION (CA) 2022-08-30 — — US disclosed
US-20220031847-A1 THERAPEUTIC METHODS GENEVANT SCIENCES GMBH (CH) 2022-02-03 — — US disclosed
CN-113365662-A Method of treatment 盖纳万科学有限公司 2021-09-07 — — CN disclosed
US-20200407724-A1 TARGETED COMPOSITIONS ARBUTUS BIOPHARMA CORPORATION (CA) 2020-12-31 — — US disclosed
US-20200407724-A1 TARGETED COMPOSITIONS ARBUTUS BIOPHARMA CORPORATION (CA) 2020-12-31 — — US disclosed
US-20190160176-A1 TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS ARBUTUS BIOPHARMA CORPORATION (CA) 2019-05-30 — — US disclosed
EP-3443092-A1 TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS Arbutus Biopharma Corporation (CA) 2019-02-20 — — EP disclosed
CN-109312342-A Target nucleic acid conjugates composition 阿布特斯生物制药公司 2019-02-05 — — CN disclosed
WO-2017177326-A1 TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS PROTIVA BIOTHERAPEUTICS, INC. (CA) 2017-10-19 — — WO disclosed
WO-2017177326-A1 TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS PROTIVA BIOTHERAPEUTICS, INC. (CA) 2017-10-19 — — WO disclosed
US-8912332-B2 Synthesis of trivalent flexible frameworks with ligands comprising catechol units for functionalizing surfaces JUSTUS-LIEBIG-UNIVERSITAET GIESSEN (DE) 2014-12-16 — — US disclosed
US-8912332-B2 Synthesis of trivalent flexible frameworks with ligands comprising catechol units for functionalizing surfaces JUSTUS-LIEBIG-UNIVERSITAET GIESSEN (DE) 2014-12-16 — — US disclosed
US-20130245270-A1 Synthesis of Trivalent Flexible Frameworks with Ligands Comprising Catechol Units for Functionalizing Surfaces JUSTUS-LIEBIG-UNIVERSITAT GIESSEN (DE) 2013-09-19 — — US disclosed
US-20130245270-A1 Synthesis of Trivalent Flexible Frameworks with Ligands Comprising Catechol Units for Functionalizing Surfaces JUSTUS-LIEBIG-UNIVERSITAT GIESSEN (DE) 2013-09-19 — — US disclosed
WO-2012032085-A1 SYNTHESIS OF TRIVALENT FLEXIBLE FRAMEWORKS WITH LIGANDS COMPRISING CATECHOL UNITS FOR FUNCTIONALIZING SURFACES JUSTUS-LIEBIG-UNIVERSITÄT GIESSEN (DE) 2012-03-15 — — WO disclosed
EP-2428503-A1 Synthesis of tripodal catechol derivatives with a flexible base for functionalising surfaces Justus-Liebig-Universität Gießen (DE) 2012-03-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190160176-A1 TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS HAVCR2, DCTD, POLRMT HTT 1642/4885KMT2A 1638/4885MEN1 2397/4885
US-20130245270-A1 Synthesis of Trivalent Flexible Frameworks with Ligands Comprising Catechol Units for Functionalizing Surfaces CHRM3, CHRM5, CHRM4 HTT 2900/4885KMT2A 1805/4885MEN1 3700/4885
US-20220031847-A1 THERAPEUTIC METHODS NUP205, HNRNPH3, FUS HTT 706/4885KMT2A 2323/4885MEN1 2150/4885
US-20230279041-A1 FUNCTIONALIZED N-ACETYLGALACTOSAMINE ANALOGS FUT6, CSGALNACT1, GALNT6 HTT 1625/4885KMT2A 2643/4885MEN1 3222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.